Redian新闻
>
看看这个分析,我又56.10买了DNDN
avatar
看看这个分析,我又56.10买了DNDN# Stock
O*L
1
Dendreon Pricing Comes in Higher-than-Expected
Dendreon Corporation (DNDN, Free Analysis), a biotechnology company focused
on cancer treatments, saw its shares jump sharply higher in early trading
after confirming approval of Provenge by the FDA and saying that its pricing
point would be around $93,000 annually, which is much higher than many
analysts were expecting.
As a result, some analysts are projecting hefty profits for the biotech firm
, ranging from $1.1 billion in 2014 to $4.3 billion b
avatar
x*l
2
5块钱的时候没看到你买

focused
pricing
firm
Dendreon
even

【在 O****L 的大作中提到】
: Dendreon Pricing Comes in Higher-than-Expected
: Dendreon Corporation (DNDN, Free Analysis), a biotechnology company focused
: on cancer treatments, saw its shares jump sharply higher in early trading
: after confirming approval of Provenge by the FDA and saying that its pricing
: point would be around $93,000 annually, which is much higher than many
: analysts were expecting.
: As a result, some analysts are projecting hefty profits for the biotech firm
: , ranging from $1.1 billion in 2014 to $4.3 billion b

avatar
O*L
3
炒过20块的,然后就没敢碰.

【在 x*******l 的大作中提到】
: 5块钱的时候没看到你买
:
: focused
: pricing
: firm
: Dendreon
: even

avatar
c*r
4
你第一把已经扔了?

focused
pricing
firm
Dendreon
even

【在 O****L 的大作中提到】
: Dendreon Pricing Comes in Higher-than-Expected
: Dendreon Corporation (DNDN, Free Analysis), a biotechnology company focused
: on cancer treatments, saw its shares jump sharply higher in early trading
: after confirming approval of Provenge by the FDA and saying that its pricing
: point would be around $93,000 annually, which is much higher than many
: analysts were expecting.
: As a result, some analysts are projecting hefty profits for the biotech firm
: , ranging from $1.1 billion in 2014 to $4.3 billion b

avatar
O*L
5
加仓.

【在 c*******r 的大作中提到】
: 你第一把已经扔了?
:
: focused
: pricing
: firm
: Dendreon
: even

avatar
n*m
6
掉下来一些了,跟你一点
投机股,进了点OPTION
avatar
n*m
7
其实我并不大了解这个公司,但是一方面你的分析挺有道理
另一方面,我的外公去世的原因,所以我对癌症大恨,对抗癌药的发明大爱
做个小股东,以防以后我和父母有啥不测,给我个机会内部治疗嘿嘿~
avatar
h*e
8
zan!
avatar
b*r
9
我觉得这个要上100。
avatar
n*m
10
...真的吗,刚补的已经被套了

【在 b******r 的大作中提到】
: 我觉得这个要上100。
avatar
h*e
11
捂就一个字

【在 n******m 的大作中提到】
: ...真的吗,刚补的已经被套了
avatar
c*4
12
in 6 six months, we will see a lot "class action lawsuit filed against DNDN"
mark my words
see too many tragedies in bio's
avatar
l*r
13
这个药好贵,医保cover嘛?
avatar
b*x
14
不懂就不要瞎说鸟,癌症药物不大容易被人抓着把柄,死了是应该的,不死是运气好
16块买的,57.5卖了今天,哈哈哈
未来几天还会pull back一点,长期很看好,被收购的可能性很大

DNDN"

【在 c*******4 的大作中提到】
: in 6 six months, we will see a lot "class action lawsuit filed against DNDN"
: mark my words
: see too many tragedies in bio's

avatar
c*4
15
a buyout by who?
CTIC had a long ride from cents, so what?
I just warn people about risk.
You know a lot, then tell us what you know about it?

【在 b***x 的大作中提到】
: 不懂就不要瞎说鸟,癌症药物不大容易被人抓着把柄,死了是应该的,不死是运气好
: 16块买的,57.5卖了今天,哈哈哈
: 未来几天还会pull back一点,长期很看好,被收购的可能性很大
:
: DNDN"

avatar
c*x
16
Roche(Genentech) is rumored to be #1 buyer. SNY is rumored to be #2 as
Provenge will displace Taxoter.

【在 c*******4 的大作中提到】
: a buyout by who?
: CTIC had a long ride from cents, so what?
: I just warn people about risk.
: You know a lot, then tell us what you know about it?

avatar
g*u
17
这个公司现在价已经6B。 脚得它值几钱?
不能比PFE的Lipitor值钱吧?
我脚的60亿可能已经Hype太大了。x10不可能吧。How about
x5 (still unlikely)
x3 (maybe still push it)
x2? Not entirely unlikely.
这个公司药本身意义有限。关键看是否掌握相关一类制程的专利。好比那个干细胞的技
术,那个是核心专利,所有的line如果是商用都得给他上税。
相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。